WORLD PEPTIDEFOUNDATION

Where is BPC-157 being studied?

Find registered human studies, phases, products, recruitment status and reported research locations around the world. Registry search matches are separate from this profile’s reviewed evidence.

Find studies for BPC-157 →Worldwide registry directory
Search this profile’s alternative names

Check the intervention identity in each registry record; aliases and combination products can produce broader matches.

Scientific intelligence record

Experience 2.0

Synthetic research peptide

BPC-157

Also known as: Body Protection Compound 157, PL 14736, Bepecin

BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence associated with gastric proteins. Experimental studies report effects on angiogenesis, nitric-oxide signaling, inflammatory pathways, and tissue repair, but the proposed mechanisms are not established as therapeutic mechanisms in humans.

Record status

Traceability partial

Last meaningful update: 9/8/2026

Evidence searched through:
Not recorded
Assessment updated:
9/8/2026
Documented human review:
No documented human review recorded
Automated scientific assessment:
9/8/2026
AI source check:
9/26/2026

Published source links and profile text pass separate gates. Only a documented human review is labelled as human review; an automated scientific assessment applies deterministic checks, and an AI source check confirms only that a source exists and matches its identifiers. A source count alone does not establish a review.

Evidence coverage has three distinct layers. The corpus count is a transparent screening inventory, the featured set contains study-level tiering and interpretation, and the published-source count contains records promoted through the institutional publication workflow. Source validation, editorial publication, and scientific appraisal are separate decisions; these numbers must not be merged.

Ranked research corpus

220

Categorized publications with provisional ranking; scientific review remains separate.

Featured tiered studies

1

Cornerstone publications with study-level interpretation, limitations, and tier disclosure.

Research domains

14

Clinical and scientific questions synthesized independently across the evidence atlas.

Published source records

25

Database records promoted through the governed publication workflow—not the corpus total.

Corpus generated 2026-09-18. Counts remain separately labeled so screening is not represented as completed review.

Human experience · separate evidence stream

No community pattern is displayed yet

Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.

Observation is valuable human context. It is not evidence of causation, efficacy, or safety.

Public display gate

n ≥ 20 eligible observations

Exact progress remains private before the threshold.

Contribute an observationArchive details

Intelligence snapshot

The state of the record

A compact view of what is represented, what remains unresolved, and how completely the record can be traced.

Ranked research corpus

220

Categorized screening records; proposed rankings remain pending human appraisal.

Featured tiered studies

1

Cornerstone studies with published study-level interpretation and tier disclosure.

Research domains

14

Independent evidence dossiers covering the major research questions.

Published source records

25

Source records published through the governed workflow; this count does not certify scientific conclusions.

Contradictions

0

Conflicting evidence relationships that remain visible.

Research gaps

1

Questions the current record identifies as unresolved.

Connected media

0

Media records explicitly linked to this scientific record.

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

Reconciled domain conclusions

14 published domain syntheses connected to 1 featured studies

BPC-157 no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded synthesis, confidence level, evidence context, limitations, geographic applicability, regulatory interpretation, and research gaps. Publication of these syntheses is separate from the scientific review status shown above.

Inspect the reconciled evidence atlas
Inspect the published evidence record25 governed records · titles, provenance, and original-source linksOpen records ↓
2025Phase 1–2 human evidence
Evidence strength B · 70/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
60/100
Directness
88/100
Population relevance
65/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?

Very early in vivo research on pharmacokinetics indicates the possibility that body protection compound 157 (BPC-157) is at the forefront of therapeutic peptides, with early demonstrations of this experimental peptide optimizing endurance training, metabolism …

Authors
DeFoor MT, Dekker TJ.
Source
peer_reviewed_research
DOI
10.1016/j.arthro.2024.09.005
PubMed
39265666
Open original source
2021Phase 1–2 human evidence
Evidence strength B · 74/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
68/100
Directness
88/100
Population relevance
78/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.

The other 4 patients received a combination of 2 peptide injections of BPC 157 and TB4. Of the patients who received both peptides, 75% showed significant improvement, but 25% had no relief of their knee pain. Overall, 14 of 16 patients (87.5%) had relief of their k …

Authors
Lee E, Padgett B.
Source
peer_reviewed_research
PubMed
34324435
Open original source
2026Phase 1–2 human evidence
Evidence strength B · 74/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
68/100
Directness
88/100
Population relevance
78/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (anti-obesity drug 9604), BPC-157 (body protection compound 157), CJC-129 …

Authors
Mendias CL, Awan TM.
Source
peer_reviewed_research
DOI
10.1007/s40279-026-02437-0
PubMed
41966639
Open original source
2025Phase 1–2 human evidence
Evidence strength B · 76/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
68/100
Directness
88/100
Population relevance
78/100
Reporting quality
68/100
Replication
72/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.

RECENT FINDINGS: BPC-157 is a synthetic pentadecapeptide originally isolated from gastric juice and has demonstrated regenerative properties across numerous animal models. ...Until well-designed clinical trials are conducted, BPC-157 should be consider …

Authors
McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM.
Source
peer_reviewed_research
DOI
10.1007/s12178-025-09990-7
PubMed
40789979
Open original source
2024Phase 1–2 human evidence
Evidence strength B · 74/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
68/100
Directness
88/100
Population relevance
78/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.

Although pentosan polysulfate is an approved treatment for interstitial cystitis, some patients on this medication experience treatment failure after one year, and its long-term use has been linked to pigmentary maculopathy. The peptide Body Protective Compound 157 (BPC …

Authors
Lee E, Walker C, Ayadi B.
Source
peer_reviewed_research
PubMed
39325560
Open original source
2025Observational human evidence
Evidence strength B · 70/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
56/100
Directness
88/100
Population relevance
72/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.

BACKGROUND: For years, the peptide Body Protection Compound 157 (BPC-157) has been used to treat partial muscle or tendon tears. Few studies on humans have been published, with none on the intravenous use of BPC-157 in humans. ...The results of …

Authors
Lee E, Burgess K.
Source
peer_reviewed_research
PubMed
40131143
Open original source
2025Observational human evidence
Evidence strength B · 75/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
72/100
Directness
88/100
Population relevance
65/100
Reporting quality
68/100
Replication
72/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.

Background: Body protection compound-157 (BPC-157) is a naturally occurring gastric peptide that promotes mucosal integrity and homeostasis. ...Review of the Musculoskeletal Literature Surrounding a Relatively Novel Peptide, Body Protection Compound-157 Body …

Authors
Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM.
Source
peer_reviewed_research
DOI
10.1177/15563316251355551
PubMed
40756949
Open original source
2022Animal research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
46/100
Directness
88/100
Population relevance
25/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Pentadecapeptide BPC 157 and the central nervous system.

Firstly, given in the reperfusion, BPC 157 counteracted bilateral clamping of the common carotid arteries-induced stroke, sustained brain neuronal damages were resolved in rats as well as disturbed memory, locomotion, and coordination. ...Thus, these disturbances ma …

Authors
Vukojevic J, Milavić M, Perović D, Ilić S, Čilić AZ, Đuran N, Štrbe S, Zoričić Z, Filipčić I, Brečić P, Seiverth S, Sikirić P.
Source
peer_reviewed_research
DOI
10.4103/1673-5374.320969
PubMed
34380875
Open original source
2020Animal research
Evidence strength C · 63/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
46/100
Directness
88/100
Population relevance
25/100
Reporting quality
68/100
Replication
72/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy.

This review is focused on the healing of fistulas and stable gastric pentadecapeptide BPC 157. Assuming that the healing of the various wounds is essential also for the gastrointestinal fistulas healing, the healing effect on fistulas in rats, consistently noted wit …

Authors
Sikiric P, Drmic D, Sever M, Klicek R, Blagaic AB, Tvrdeic A, Kralj T, Kovac KK, Vukojevic J, Siroglavic M, Gojkovic S, Krezic I, Pavlov KH, Rasic D, Mirkovic I, Kokot A, Skrtic A, Seiwerth S.
Source
peer_reviewed_research
DOI
10.2174/1381612826666200424180139
PubMed
32329684
Open original source
1985Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.

This study was designed to investigate the potential mechanism of BPC 157 to enhance healing of injured tendon. The outgrowth of tendon fibroblasts from tendon explants cultured with or without BPC 157 was examined. ...BPC 157 also dose d …

Authors
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH.
Source
peer_reviewed_research
DOI
10.1152/japplphysiol.00945.2010
PubMed
21030672
Open original source
2026Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

By acting on key pathways such as PI3K/Akt, mTOR, MAPK, TGF-beta, and AMPK, peptides exert influence over tissue regeneration, inflammation resolution, and neuromuscular recovery. Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integ …

Authors
Rahman OF, Lee SJ, Seeds WA.
Source
peer_reviewed_research
DOI
10.5435/JAAOSGlobal-D-25-00236
PubMed
41490200
Open original source
2026Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

METHODS: A comprehensive literature search was conducted using PubMed to identify biochemical and clinical studies on the most popular types of injectable peptide therapy. Key peptides evaluated included BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and …

Authors
Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE.
Source
peer_reviewed_research
DOI
10.1177/03635465251357593
PubMed
41476424
Open original source
2018Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.

Thereby, we focused on the stable gastric pentadecapeptide BPC 157, a peptide given always alone vs. standard peptidergic angiogenic growth factors (EGF, FGF, VEGF), and numerous carriers. ...Thus, we claim that just BPC 157 represents in practice a ph …

Authors
Seiwerth S, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, Drmic D, Stupnisek M, Misic M, Vuletic LB, Pavlov KH, Barisic I, Kokot A, Japjec M, Blagaic AB, Tvrdeic A, Rokotov DS, Vrcic H, Staresinic M, Sebecic B, Sikiric P.
Source
peer_reviewed_research
DOI
10.2174/1381612824666180712110447
PubMed
29998800
Open original source
2021Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.

Likewise, BPC 157 may prevent and/or attenuate or eliminate, thus, counteract both arterial and venous thrombosis. Then, confronted with obstructed vessels, there is circumvention of the occlusion, which may be the particular action of BPC 157 in ische …

Authors
Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB, Pavlov KH, Petrovic A, Sikiric S, Vranes H, Prtoric A, Zizek H, Durasin T, Dobric I, Staresinic M, Strbe S, Knezevic M, Sola M, Kokot A, Sever M, Lovric E, Skrtic A, Blagaic AB, Sikiric P.
Source
peer_reviewed_research
DOI
10.3389/fphar.2021.627533
PubMed
34267654
Open original source
2019Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.

Currently, all studies investigating BPC 157 have demonstrated consistently positive and prompt healing effects for various injury types, both traumatic and systemic and for a plethora of soft tissues. ...Promisingly, there are few studies reporting any adverse reac …

Authors
Gwyer D, Wragg NM, Wilson SL.
Source
peer_reviewed_research
DOI
10.1007/s00441-019-03016-8
PubMed
30915550
Open original source
2016Laboratory research
Evidence strength C · 63/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
72/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.

METHODS: Review of our research on BPC 157 in terms of brain-gut axis. RESULTS: BPC 157 may serve as a novel mediator of Robert's cytoprotection, involved in maintaining of GI mucosa integrity, with no toxic effect. ...CONCLUSION: BPC 157 …

Authors
Sikiric P, Seiwerth S, Rucman R, Kolenc D, Vuletic LB, Drmic D, Grgic T, Strbe S, Zukanovic G, Crvenkovic D, Madzarac G, Rukavina I, Sucic M, Baric M, Starcevic N, Krstonijevic Z, Bencic ML, Filipcic I, Rokotov DS, Vlainic J.
Source
peer_reviewed_research
DOI
10.2174/1570159x13666160502153022
PubMed
27138887
Open original source
2025Laboratory research
Evidence strength C · 63/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
72/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.

Unlike many other drugs, BPC 157 has a desirable safety profile, since only a few side effects have been reported following its administration. ...This generated the attention of experts, as BPC 157 has been offered for sale on many websites. We also p …

Authors
Józwiak M, Bauer M, Kamysz W, Kleczkowska P.
Source
peer_reviewed_research
DOI
10.3390/ph18020185
PubMed
40005999
Open original source
2022Laboratory research
Evidence strength C · 63/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
72/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle.

As a follow up, we reviewed that with the BPC 157 therapy, its cytoprotective ability to organize simultaneous healing of different tissues of and full recovery of the myotendinous junction might represent the particular muscle therapy against distinctive etiopathol …

Authors
Staresinic M, Japjec M, Vranes H, Prtoric A, Zizek H, Krezic I, Gojkovic S, Smoday IM, Oroz K, Staresinic E, Dretar V, Yago H, Milavic M, Sikiric S, Lovric E, Batelja Vuletic L, Simeon P, Dobric I, Strbe S, Kokot A, Vlainic J, Blagaic AB, Skrtic A, Seiwerth S, Sikiric P.
Source
peer_reviewed_research
DOI
10.3390/biomedicines10123221
PubMed
36551977
Open original source
1997Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

BPC 157's effect on healing.

In all experiments significant differences between BPC 157-treated animals and controls were found, showing a strong, promoting involvement of BPC in the healing process. It is worth noting that these effects were achieved by different routes of application, includi …

Authors
Seiwerth S, Sikiric P, Grabarevic Z, Zoricic I, Hanzevacki M, Ljubanovic D, Coric V, Konjevoda P, Petek M, Rucman R, Turkovic B, Perovic D, Mikus D, Jandrijevic S, Medvidovic M, Tadic T, Romac B, Kos J, Peric J, Kolega Z.
Source
peer_reviewed_research
DOI
10.1016/s0928-4257(97)89480-6
PubMed
9403790
Open original source
2026Laboratory research
Evidence strength C · 63/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
72/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Peptide Supplements and Their Therapeutic Applications in Sports Medicine.

PURPOSE: To summarize existing peer-reviewed data on 6 emerging peptides (BPC-157, thymosin beta-4 or TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu [copper peptide]) for musculoskeletal recovery and enhancement in animal and human models. ...METHODS: Three indepe …

Authors
Tewari K, Liu TP, Im C, Hamad C, Petrigliano F, Cheung EC, Kremen TJ Jr.
Source
peer_reviewed_research
DOI
10.1177/03635465261464420
PubMed
42578445
Open original source
2020Laboratory research
Evidence strength C · 63/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
72/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection.

In this background, we put the importance of BPC 157 as a possible way of securing GI safety against NSAIDs-induced gastroenteropathy since still unmet medical needs to mitigate NSAIDs-induced cytotoxicity are urgent. ...In this review article, we described the pote …

Authors
Park JM, Lee HJ, Sikiric P, Hahm KB.
Source
peer_reviewed_research
DOI
10.2174/1381612826666200523180301
PubMed
32445447
Open original source
2023Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Stable Gastric Pentadecapeptide BPC 157: Prompt Particular Activation of Collateral Pathways.

This peer-reviewed source examines Stable Gastric Pentadecapeptide BPC 157: Prompt Particular Activation of Collateral Pathways.

Authors
Sikiric P, Gojkovic S, Knezevic M, Tepes M, Strbe S, Vukojevic J, Duzel A, Kralj T, Krezic I, Zizek H, Oroz K, Vranes H, Smoday IM, Kalogjera L, Vlainic J, Kokot A, Jurjevic I, Blagaic AB, Skrtic A, Seiwerth S.
Source
peer_reviewed_research
DOI
10.2174/0929867329666221005111553
PubMed
36200148
Open original source
2014Laboratory research
Evidence strength C · 63/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
72/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Stable gastric pentadecapeptide BPC 157-NO-system relation.

We reviewed stable gastric pentadecapeptide BPC 157-NO-system-relation, its close participation in Moncada's (maintained vascular integrity, platelets control) homeostatic healing response of NO-system to injury. Namely, BPC 157's particular healing ef …

Authors
Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica G, Stupnisek M, Suran J, Barisic I, Dzidic S, Vrcic H, Sebecic B.
Source
peer_reviewed_research
DOI
10.2174/13816128113190990411
PubMed
23755725
Open original source
2025Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT).

This peer-reviewed source examines Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT).

Authors
Whitehouse M.
Source
peer_reviewed_research
DOI
10.1007/s10787-025-01882-z
PubMed
40759852
Open original source
2014Laboratory research
Evidence strength C · 63/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
72/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

BPC 157 and blood vessels.

This review focuses on the described effects of BPC 157 on blood vessels after different types of damage, and elucidate by investigating different aspects of vascular response to injury (endothelium damage, clotting, thrombosis, vasoconstriction, vasodilatation, vas …

Authors
Seiwerth S, Brcic L, Vuletic LB, Kolenc D, Aralica G, Misic M, Zenko A, Drmic D, Rucman R, Sikiric P.
Source
peer_reviewed_research
DOI
10.2174/13816128113199990421
PubMed
23782145
Open original source

Scientific context

Chemistry and represented biological context

Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.

Open chemistry and biological context ↓
Chemical identity

Molecular and structural record

Structured record
Molecular formula
C62H98N16O22
Molecular weight (Da)
1419.56
Amino acid sequence
GEPPPGKPADDAGLV

Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.

Explore further

Continue through the research system

Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.

Research discovery

Compare peptides

Examine represented peptide records side by side.

Evidence system

Explore how scientific evidence is represented and reviewed.

Research hub

Enter the broader research and intelligence environment.

Methodology

Review project methods, boundaries, and interpretation rules.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

  1. 1985 · study · Temporal status not established

    The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.

    peer_reviewed_research

  2. 1997 · study · Temporal status not established

    BPC 157's effect on healing.

    peer_reviewed_research

  3. 2014 · study · Temporal status not established

    Stable gastric pentadecapeptide BPC 157-NO-system relation.

    peer_reviewed_research

  4. 2014 · study · Temporal status not established

    BPC 157 and blood vessels.

    peer_reviewed_research

  5. 2016 · study · Temporal status not established

    Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.

    peer_reviewed_research

  6. 2018 · study · Temporal status not established

    BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.

    peer_reviewed_research

  7. 2019 · study · Temporal status not established

    Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.

    peer_reviewed_research

  8. 2020 · study · Temporal status not established

    Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy.

    peer_reviewed_research

  9. 2020 · study · Temporal status not established

    BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection.

    peer_reviewed_research

  10. 2021 · study · Temporal status not established

    Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.

    peer_reviewed_research

  11. 2021 · study · Temporal status not established

    Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.

    peer_reviewed_research

  12. 2022 · study · Temporal status not established

    Pentadecapeptide BPC 157 and the central nervous system.

    peer_reviewed_research

  13. 2022 · study · Temporal status not established

    Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle.

    peer_reviewed_research

  14. 2023 · study · Temporal status not established

    Stable Gastric Pentadecapeptide BPC 157: Prompt Particular Activation of Collateral Pathways.

    peer_reviewed_research

  15. 2024 · study · Temporal status not established

    Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.

    peer_reviewed_research

  16. 2025 · study · Temporal status not established

    Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?

    peer_reviewed_research

  17. 2025 · study · Temporal status not established

    Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.

    peer_reviewed_research

  18. 2025 · study · Temporal status not established

    Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.

    peer_reviewed_research

  19. 2025 · study · Temporal status not established

    Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.

    peer_reviewed_research

  20. 2025 · study · Temporal status not established

    Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.

    peer_reviewed_research

  21. 2025 · study · Temporal status not established

    Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT).

    peer_reviewed_research

  22. 2026 · study · Temporal status not established

    Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

    peer_reviewed_research

  23. 2026 · study · Temporal status not established

    Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

    peer_reviewed_research

  24. 2026 · study · Temporal status not established

    Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

    peer_reviewed_research

  25. 2026 · study · Temporal status not established

    Peptide Supplements and Their Therapeutic Applications in Sports Medicine.

    peer_reviewed_research

  26. 2026 · regulatory · Temporal status not established

    Regulatory review: not_approved

    European Union (EMA)

  27. 2026 · regulatory · Temporal status not established

    Regulatory review: not_approved

    United States (FDA)

The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.

What still needs investigation

Claim traceability

No institutional claim record is currently represented for this peptide.

Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.

Researchers represented in the evidence record12 bibliographic identities · open to inspect

These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.

Seiwerth S

9 represented evidence records

Years represented: 1997, 2014, 2016, 2018, 2020, 2021, 2022, 2023

Publishing organizations appearing in records: peer_reviewed_research

Sikiric P

10 represented evidence records

Years represented: 1997, 2014, 2016, 2018, 2020, 2021, 2022, 2023

Publishing organizations appearing in records: peer_reviewed_research

Blagaic AB

5 represented evidence records

Years represented: 2018, 2020, 2021, 2022, 2023

Publishing organizations appearing in records: peer_reviewed_research

Kokot A

5 represented evidence records

Years represented: 2018, 2020, 2021, 2022, 2023

Publishing organizations appearing in records: peer_reviewed_research

Drmic D

5 represented evidence records

Years represented: 2014, 2016, 2018, 2020

Publishing organizations appearing in records: peer_reviewed_research

Gojkovic S

4 represented evidence records

Years represented: 2020, 2021, 2022, 2023

Publishing organizations appearing in records: peer_reviewed_research

Krezic I

4 represented evidence records

Years represented: 2020, 2021, 2022, 2023

Publishing organizations appearing in records: peer_reviewed_research

Rucman R

5 represented evidence records

Years represented: 1997, 2014, 2016, 2018

Publishing organizations appearing in records: peer_reviewed_research

Sever M

4 represented evidence records

Years represented: 2014, 2018, 2020, 2021

Publishing organizations appearing in records: peer_reviewed_research

Sikiric P.

4 represented evidence records

Years represented: 2014, 2018, 2021, 2022

Publishing organizations appearing in records: peer_reviewed_research

Skrtic A

4 represented evidence records

Years represented: 2020, 2021, 2022, 2023

Publishing organizations appearing in records: peer_reviewed_research

Strbe S

4 represented evidence records

Years represented: 2016, 2021, 2022, 2023

Publishing organizations appearing in records: peer_reviewed_research

Connections

Follow the scientific relationships

Connections appear only when they are represented by the project’s underlying records.

Open 1 represented connection ↓

institution

peer_reviewed_research

represented evidence source

Traceability

Follow the record back to its source

The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.

Source publication state

A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.

Reviewer provenance state

“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.

Domain conclusion → Evidence

Connected

Evidence → Source

Connected

Source → Original record

Connected

Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.

Reconciled for 14 domain conclusions and 1 featured studies.

Detailed study-to-domain mappings and original-source paths appear in the BPC-157 evidence-governance section.

Inspect the ranked source records

Observational archive

What contributors reported

Observational archive data is intentionally separated from published scientific evidence.

Observational boundary

Insufficient eligible observations are available for display under the current filters.

Insufficient eligible observations are currently represented to display aggregated findings for this peptide.

Regulatory context

Published jurisdictional records

Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.

Research + media

Media connected to this scientific record

Only media explicitly linked through the project’s relationship system appears here.

No scientifically connected media is currently represented for this peptide.

Sources + provenance

Read the scientific record with its boundaries intact

The public record organizes reviewed evidence; it does not establish scientific truth by itself.
Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.
Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.
Contradictory and qualifying evidence must remain visible rather than being silently discarded.
Absence of represented evidence is not evidence that research does not exist.
Research gaps identify unresolved questions; they are not negative conclusions.
Regulatory status is distinct from scientific evidence quality.
Media relationships provide context and explanation; they do not increase the strength of scientific evidence.
A section with no represented records is an incomplete project record, not a scientific conclusion.
Researcher and institutional relationships are shown only when supported by represented records and must not be interpreted as rankings or endorsements.

Generated: 11/8/2026, 5:28:46 PM

global evidence atlas

BPC-157 research, ranked and separated by purpose

This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

Investigational boundary: BPC-157 is not presented here as FDA-approved, and screening records must not be interpreted as established clinical benefit.

220Discoverable source universe
220Ranked screening records
14Research domains
24Governed published sources

220 matching records · ranked 2026-09-18

Page 1 of 9

#2Proposed tier Bclinical trial or protocolAwaiting human appraisal

Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system.

Journal of pharmacological sciences · 2008 Sep · PMID 18818478 · DOI 10.1254/jphs.fp0072161

Gastrointestinal research · Wound healing and angiogenesis · Human clinical evidence · Animal and preclinical evidence · Mechanism and pharmacology

#10Proposed tier CreviewAwaiting human appraisal

BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185.

Pharmaceuticals (Basel, Switzerland) · 2025 Sep 28 · PMID 41155565 · DOI 10.3390/ph18101450

Wound healing and angiogenesis · Toxicology and safety · Animal and preclinical evidence · Mechanism and pharmacology

#11Proposed tier CreviewAwaiting human appraisal

Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on "Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185".

Pharmaceuticals (Basel, Switzerland) · 2025 Sep 28 · PMID 41155566 · DOI 10.3390/ph18101451

Wound healing and angiogenesis · Toxicology and safety · Animal and preclinical evidence · Mechanism and pharmacology

#12Proposed tier CreviewAwaiting human appraisal

Challenge of Corneal Ulcer Healing: A Novel Conceptual Framework, the "Triad" of Corneal Ulcer Healing/Corneal Neovascularization/Intraocular Pressure, and Avascular Tendon Healing, for Evaluation of Corneal Ulcer Therapy, Therapy of Neovascularization, Glaucoma Therapy, and Pentadecapeptide BPC 157 Efficacy.

Pharmaceuticals (Basel, Switzerland) · 2025 Nov 28 · PMID 41471311 · DOI 10.3390/ph18121822

Musculoskeletal and tendon research · Gastrointestinal research · Wound healing and angiogenesis · Mechanism and pharmacology

Count reconciliation: 220 discoverable source records match the peptide identity query; 220 are retained in this bounded, ranked screening view; 24 belong to the separate governed layer labeled “Governed published sources.” Domain totals overlap because one publication may inform several questions.

BPC-157 evidence · ranking key

How evidence is ranked

A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.

A

Practice-defining evidence

Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.

B

Strong supporting evidence

Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.

C

Contextual evidence

Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.

D

Signal-generating evidence

Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.

Tier and confidence answer different questions

Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.

Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.

peptide explorer

Structural visualization and provenance

Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.

Fully specified molecular identity

Molecular formula
C62H98N16O22
Molecular weight
1419.54 g/mol
Exact identity / sequence notation
H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH
Identity-defining modifications
  • 15-residue synthetic gastric pentadecapeptide
  • Unmodified N-terminus and free C-terminal carboxyl
PubChem CID
9941957
InChIKey
Not applicable / not verified

Complete sequence and formula are registry-backed; no verified experimental or predicted coordinate record is asserted.

Sources: NIH PubChem — BPC-157 · reviewed 2026-09-17

Representative sequence-derived model
Structure source
Generated from this record's governed amino-acid sequence
Identifier
Not applicable — not a database structure
Method
Schematic layout ordered by residue position only; not a molecular-dynamics, homology, or fold prediction
Confidence / limitations
Illustrative only. Not physically accurate; carries no structural, binding-site, or activity meaning.
Provenance
WPF governed PeptideChemistry record
Retrieved / last reviewed
2026-09-17

This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.

Suggested citation

  • APA

    World Peptide Foundation. (n.d.). BPC-157 — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 8, 2026.) https://www.worldpeptidefoundation.org/directory/bpc-157

  • AMA / Vancouver

    World Peptide Foundation. BPC-157 — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 8, 2026. https://www.worldpeptidefoundation.org/directory/bpc-157